CA3128987A1 - Connexin 43 antibodies and use thereof - Google Patents

Connexin 43 antibodies and use thereof Download PDF

Info

Publication number
CA3128987A1
CA3128987A1 CA3128987A CA3128987A CA3128987A1 CA 3128987 A1 CA3128987 A1 CA 3128987A1 CA 3128987 A CA3128987 A CA 3128987A CA 3128987 A CA3128987 A CA 3128987A CA 3128987 A1 CA3128987 A1 CA 3128987A1
Authority
CA
Canada
Prior art keywords
antibody
fragment
seq
binding
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3128987A
Other languages
English (en)
French (fr)
Inventor
Yanfeng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alamab Therapeutics Inc
Original Assignee
Alamab Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alamab Therapeutics Inc filed Critical Alamab Therapeutics Inc
Publication of CA3128987A1 publication Critical patent/CA3128987A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Computer And Data Communications (AREA)
CA3128987A 2019-02-04 2020-02-04 Connexin 43 antibodies and use thereof Pending CA3128987A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962800869P 2019-02-04 2019-02-04
US62/800,869 2019-02-04
PCT/US2020/016606 WO2020163353A1 (en) 2019-02-04 2020-02-04 Connexin 43 antibodies and use thereof

Publications (1)

Publication Number Publication Date
CA3128987A1 true CA3128987A1 (en) 2020-08-13

Family

ID=71947290

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3128987A Pending CA3128987A1 (en) 2019-02-04 2020-02-04 Connexin 43 antibodies and use thereof

Country Status (9)

Country Link
US (2) US12187794B2 (enExample)
EP (1) EP3920969A4 (enExample)
JP (2) JP7709917B2 (enExample)
KR (1) KR20210153039A (enExample)
CN (2) CN119700967A (enExample)
AU (3) AU2020219112A1 (enExample)
CA (1) CA3128987A1 (enExample)
IL (2) IL320816A (enExample)
WO (1) WO2020163353A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12227561B2 (en) 2018-04-02 2025-02-18 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
CA3190474A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
WO2025006774A1 (en) * 2023-06-30 2025-01-02 Alamab Therapeutics, Inc. Method of treating osteoarthritis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO2003057881A1 (en) * 2001-12-28 2003-07-17 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
US6745478B2 (en) 2002-07-18 2004-06-08 Delillo Dominick D. Multi-purpose work knife
ES2399050T3 (es) * 2003-12-10 2013-03-25 Medarex, Inc. Anticuerpos contra interferón alfa y sus usos
EP2662088A3 (en) 2005-02-03 2014-02-19 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
JP2011523414A (ja) * 2008-05-15 2011-08-11 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｆｎ１４抗体、およびその使用
JP2011524345A (ja) 2008-06-04 2011-09-01 コーダ セラピューティクス， インコーポレイテッド ギャップジャンクション調節化合物を用いる疼痛の治療
CA2823154A1 (en) 2010-12-27 2012-07-05 Lsip, Llc Ips cells and method for generating same
CN114621346B (zh) * 2013-08-21 2025-06-10 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
JP6683686B2 (ja) 2014-08-22 2020-04-22 オークランド ユニサービシーズ リミティド チャネル調節剤
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
EP3419998A4 (en) * 2016-02-26 2019-09-25 The Board of Regents of The University of Texas System CONNEXIN (CX) 43 HEMICANAL BINDING ANTIBODIES AND USES THEREOF
US12227561B2 (en) 2018-04-02 2025-02-18 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
CA3190474A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations

Also Published As

Publication number Publication date
AU2022218583A1 (en) 2022-10-06
AU2022218583B9 (en) 2025-12-04
CN112384244A (zh) 2021-02-19
US12187794B2 (en) 2025-01-07
IL285369A (en) 2021-09-30
AU2026201299A1 (en) 2026-03-12
KR20210153039A (ko) 2021-12-16
CN119700967A (zh) 2025-03-28
JP7709917B2 (ja) 2025-07-17
CN112384244B (zh) 2025-01-24
AU2020219112A1 (en) 2021-08-26
US20220411494A1 (en) 2022-12-29
WO2020163353A1 (en) 2020-08-13
JP2022519293A (ja) 2022-03-22
JP2025090679A (ja) 2025-06-17
IL285369B2 (en) 2025-10-01
EP3920969A4 (en) 2022-11-30
IL285369B1 (en) 2025-06-01
EP3920969A1 (en) 2021-12-15
US20250230233A1 (en) 2025-07-17
IL320816A (en) 2025-07-01

Similar Documents

Publication Publication Date Title
JP7829605B2 (ja) コネキシン４３抗体およびその使用
US20250230233A1 (en) Connexin 43 antibodies and use thereof
CN111704672B (zh) 抗血浆激肽释放酶抗体
JP2020079246A (ja) 糖尿病黄斑浮腫の治療のための組成物および方法
HK40043616A (en) Connexin 43 antibodies and use thereof
AU2026202530A1 (en) Connexin 43 Antibodies and Use Thereof
HK40043616B (zh) 连接蛋白43抗体及其用途
CN113842456B (zh) 一种抗人4-1bb的单克隆抗体制剂及其用途
HK40100613A (zh) 连接蛋白43抗体及其用途
HK40042791A (en) Connexin 43 antibodies and use thereof
TW202515906A (zh) 治療中風之方法
HK40112846A (zh) 抗血浆激肽释放酶抗体
TW202511285A (zh) 治療骨關節炎之方法
NZ618046B2 (en) Fc RECEPTOR BINDING PROTEINS
NZ618046A (en) Fc receptor binding proteins

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240201

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250618

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251017

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251212

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251212

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251216